A review of public information. No hands-on testing, laboratory inspection or medical review is claimed.
A service page, not a price sheet
Defy Medical’s current peptide service page names sermorelin alongside several investigational compounds and describes a lab- and symptom-led evaluation. We include a sermorelin inquiry record because the service explicitly names it. The record does not promise that any particular preparation is available to every visitor.
Sources: Defy Medical — peptide therapy, FDA — compounding substances with potential safety risks, FDA — compounding questions and answers
Historical PDFs are not current quotations
Older downloadable medication-price documents can remain searchable long after their stated date. We did not republish those figures as current. A medicine price from an old sheet would also omit whatever consultation, diagnostic and dispensing terms apply to a new patient today. The present file leaves the amount unpriced.
Sources: Defy Medical — peptide therapy, FDA — compounding substances with potential safety risks, FDA — compounding questions and answers
A named peptide is not a verified benefit
The service page discusses BPC-157, TB-500, MOTS-c and other compounds. Those descriptions should be read alongside FDA safety and compounding information, not treated as proof of efficacy. Mechanism explanations, early research and provider testimonials answer different questions from controlled clinical outcomes or product approval.
Sources: Defy Medical — peptide therapy, FDA — compounding substances with potential safety risks, FDA — compounding questions and answers
Our assessment
The page gives readers a useful list of questions for the care team, particularly which treatment is actually being considered and what testing is required. Ask for an itemized initial and follow-up budget before comparing it with a subscription clinic. We have not audited the clinic, its clinicians or its dispensing partners and do not convert the public menu into a clinical recommendation.
Sources: Defy Medical — peptide therapy, FDA — compounding substances with potential safety risks, FDA — compounding questions and answers
Every offer in our file.
Sermorelin consultation-led offering
Provider-listed prescriptionSermorelin is named on the current peptide service page. No current product-specific public quote was established.
Follow the evidence
Sources & price notes
Each source retains its own check date. Provider pages document advertised terms; they do not independently establish clinical outcomes.
- Defy Medical — peptide therapy ↗
Provider service description and care process. No current itemized medicine price was established; older downloadable pricing sheets were excluded.
Checked October 9, 2026
- FDA — compounding substances with potential safety risks ↗
Includes injectable GHK-Cu; route-specific concerns must not be applied indiscriminately to cosmetics. Regulatory page rechecked October 9, 2026; retain distinctions between approval, risk information and compounding nominations.
Checked October 9, 2026
- FDA — compounding questions and answers ↗
Clinical and regulatory context. A compounded preparation is not FDA-approved.
Checked October 8, 2026